Merck & Co is on the brink of plugging a gap in the coronavirus treatment armamentarium after its oral drug molnupiravir cut deaths and hospitalisations in mild or moderate COVID-19 in a phase 3 ...
Don't automatically throw out that old COVID-19 at-home test you just came across in your medicine cabinet. It might still be ...
A drug against fungal infections in cancer patients can last twice as long in people with obesity, and may make chemotherapy ...
The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...
While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...
Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...
Moderna said its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last iteration of the shot did in 2023.
Seeking Alpha on MSN12d
Shionogi's Xocova effective in preventing symptomatic COVID-19: studyThe drug is also approved in Singapore. Xocova belongs to the same class of drugs as Pfizer’s (PFE) Paxlovid and Merck’s (MRK ...
Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback